Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNexus Gene Lab (BGLC) Change in Account Payables (2018 - 2025)

BioNexus Gene Lab's Change in Account Payables history spans 8 years, with the latest figure at -$1.1 million for Q3 2025.

  • For Q3 2025, Change in Account Payables fell 655.8% year-over-year to -$1.1 million; the TTM value through Sep 2025 reached -$765280.0, down 178.78%, while the annual FY2024 figure was $204342.0, 153.59% up from the prior year.
  • Change in Account Payables for Q3 2025 was -$1.1 million at BioNexus Gene Lab, down from $204963.0 in the prior quarter.
  • Across five years, Change in Account Payables topped out at $649741.0 in Q4 2022 and bottomed at -$1.1 million in Q3 2025.
  • The 5-year median for Change in Account Payables is -$208629.0 (2022), against an average of -$142349.2.
  • The largest annual shift saw Change in Account Payables skyrocketed 2871.49% in 2024 before it crashed 674.94% in 2025.
  • A 5-year view of Change in Account Payables shows it stood at -$393084.0 in 2021, then skyrocketed by 265.29% to $649741.0 in 2022, then crashed by 102.57% to -$16676.0 in 2023, then surged by 2871.49% to $462174.0 in 2024, then plummeted by 341.23% to -$1.1 million in 2025.
  • Per Business Quant, the three most recent readings for BGLC's Change in Account Payables are -$1.1 million (Q3 2025), $204963.0 (Q2 2025), and -$317522.0 (Q1 2025).